141 related articles for article (PubMed ID: 3267102)
1. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
2. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
4. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
5. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
[TBL] [Abstract][Full Text] [Related]
8. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
[TBL] [Abstract][Full Text] [Related]
9. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow stromal cells in myeloproliferative disorders.
Hirata J; Takahira H; Kaneko S; Nishimura J; Nawata H
Acta Haematol; 1989; 82(1):35-9. PubMed ID: 2505472
[TBL] [Abstract][Full Text] [Related]
12. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
13. Endogenous erythroid colony formation in myeloproliferative diseases does not depend on T cells.
Robak T; Hast R; Goldman JM
Exp Hematol; 1986 Mar; 14(3):197-201. PubMed ID: 3485053
[TBL] [Abstract][Full Text] [Related]
14. Hematopathologic findings in the myeloproliferative disorders.
Dickstein JI; Vardiman JW
Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation.
Murohashi I; Endho K; Nishida S; Yoshida S; Jinnai I; Bessho M; Hirashima K
Exp Hematol; 1995 Aug; 23(9):970-7. PubMed ID: 7543418
[TBL] [Abstract][Full Text] [Related]
17. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Korycka A; Robak T
Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305
[TBL] [Abstract][Full Text] [Related]
18. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.
Escoffre-Barbe M; Amiot L; Beaucournu P; Jego P; Grulois I; Grosbois B; Bernard M; Fest T; Lamy T; Fardel O
Am J Hematol; 2006 Jul; 81(7):554-6. PubMed ID: 16755572
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of normal rat bone marrow fibroblast proliferation by sera from leukemic Fischer rats.
Bauldry SA; Wilson FD; Stromberg PC; Ackerman GA
Exp Hematol; 1985 Sep; 13(8):750-9. PubMed ID: 4043259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
